Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
79 hedge funds and large institutions have $107M invested in Agile Therapeutics in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 14 closing their positions.
209% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $497K
144% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 9
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
74% more capital invested
Capital invested by funds: $61.4M → $107M (+$45.5M)
30% more funds holding
Funds holding: 61 → 79 (+18)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.6M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.87M |
| 4 |
DCM
DG Capital Management
New York
|
+$1.47M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.23M |
| 2 |
Renaissance Technologies
New York
|
-$2.2M |
| 3 |
Millennium Management
New York
|
-$1.98M |
| 4 |
EP
Eversept Partners
New York
|
-$1.32M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.04M |
AGRX Hedge Fund Activity: Q2 2020 in Review
79 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2020, worth a combined $107M — up 74% from $61.4M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AGRX positions and 14 closed out — a net gain of 19 holders — while 22 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $10.1M. The largest seller was OrbiMed, exiting entirely with an estimated $2.23M sold.
- 79 institutional investors held Agile Therapeutics (AGRX) as of Q2 2020, up from 61 in Q1 2020.
- Funds reported $107M of Agile Therapeutics stock for Q2 2020, up 74% quarter-over-quarter.
- 33 funds opened new Agile Therapeutics positions in Q2 2020 and 14 closed out, a net change of +19 holders.
- The largest Agile Therapeutics buyer in Q2 2020 was BlackRock, an estimated $10.1M added.
- The largest Agile Therapeutics seller in Q2 2020 was OrbiMed, an estimated $2.23M sold.
Based on aggregated 13F filings for Q2 2020.